Laboratory Co. of America Holdings (NYSE:LH - Get Free Report) CAO Peter J. Wilkinson sold 2,439 shares of the firm's stock in a transaction on Monday, April 29th. The shares were sold at an average price of $204.33, for a total value of $498,360.87. Following the transaction, the chief accounting officer now directly owns 2,087 shares of the company's stock, valued at approximately $426,436.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Laboratory Co. of America Stock Performance
LH stock traded down $0.05 during midday trading on Wednesday, reaching $201.32. 765,346 shares of the company's stock traded hands, compared to its average volume of 768,151. The company has a current ratio of 0.88, a quick ratio of 0.76 and a debt-to-equity ratio of 0.39. The stock has a market cap of $16.94 billion, a P/E ratio of 40.52, a PEG ratio of 1.54 and a beta of 1.01. Laboratory Co. of America Holdings has a 52-week low of $174.20 and a 52-week high of $234.09. The stock's 50-day moving average is $211.16 and its 200 day moving average is $214.89.
Laboratory Co. of America (NYSE:LH - Get Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.20. The company had revenue of $3.18 billion during the quarter, compared to analyst estimates of $3.12 billion. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The firm's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.82 EPS. As a group, analysts anticipate that Laboratory Co. of America Holdings will post 14.87 EPS for the current year.
Laboratory Co. of America Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, May 28th. This represents a $2.88 dividend on an annualized basis and a yield of 1.43%. Laboratory Co. of America's payout ratio is presently 57.95%.
Hedge Funds Weigh In On Laboratory Co. of America
Hedge funds have recently made changes to their positions in the business. Provence Wealth Management Group bought a new position in shares of Laboratory Co. of America during the 3rd quarter valued at about $29,000. Mendota Financial Group LLC bought a new stake in Laboratory Co. of America in the 4th quarter worth approximately $29,000. Tradewinds Capital Management LLC purchased a new stake in shares of Laboratory Co. of America during the 3rd quarter worth approximately $34,000. Exchange Traded Concepts LLC purchased a new position in shares of Laboratory Co. of America in the third quarter valued at $37,000. Finally, Bruce G. Allen Investments LLC purchased a new stake in Laboratory Co. of America during the fourth quarter valued at $60,000. Institutional investors own 95.94% of the company's stock.
Wall Street Analysts Forecast Growth
LH has been the topic of several research reports. Robert W. Baird dropped their price objective on shares of Laboratory Co. of America from $255.00 to $244.00 and set an "outperform" rating on the stock in a research note on Friday, April 26th. Evercore ISI began coverage on Laboratory Co. of America in a research report on Friday, February 9th. They set an "in-line" rating and a $240.00 price objective for the company. Truist Financial cut their target price on Laboratory Co. of America from $270.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, April 26th. TheStreet lowered shares of Laboratory Co. of America from a "b-" rating to a "c+" rating in a research note on Thursday, February 15th. Finally, Leerink Partnrs reaffirmed an "outperform" rating on shares of Laboratory Co. of America in a report on Monday, February 26th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $243.14.
Read Our Latest Research Report on Laboratory Co. of America
Laboratory Co. of America Company Profile
(
Get Free Report)
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Laboratory Co. of America, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Laboratory Co. of America wasn't on the list.
While Laboratory Co. of America currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
